Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

OGXI $2.68 0.2650 +11.00%
BLRX $2.47 0.2300 +10.27%
GTXI $0.82 0.0705 +9.40%
ONCY $1.16 0.0900 +8.41%
CVM $1.17 0.0900 +8.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

MNKD $6.01 -0.6350 -9.56%
CALA $12.65 -1.1101 -8.07%
CERU $7.59 -0.6535 -7.93%
SNSS $2.06 -0.1499 -6.78%
FPRX $24.62 -1.4700 -5.63%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

First-in Man: Tumor Suctioned From Vein to Allow For Kidney Surgery

(Henry Ford Health System) Feb 11, 2015 - Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal.
read press release 

Mutation Order in Tumor Genes Affects Cancer Outcome

(Scientific American) Feb 11, 2015 - For the first time, researchers have proved that the order in which cancer genes mutate affects the type of malignancy that results and its response to treatment.
read article 

Stroke Survivors May Be at Higher Risk of Having Cancer

(American Heart Association) Feb 12, 2015 - People who had a stroke may develop cancer at a higher rate than those who do not have a stroke, according to research presented at the American Stroke Association’s International Stroke Conference 2015.
read press release 

Lenvatinib Highly Beneficial in Advanced Thyroid Cancer

(Medscape Medical News) Feb 11, 2015 - The investigational agent lenvatinib significantly increased progression-free survival and response rates in patients with iodine-131 refractory thyroid cancer in a phase 3 trial.
read article (free registration required) 

Sanofi Shrinks Cancer Research and Revamps R&D, Cutting 100 Jobs

(Wall Street Journal/Pharmalot blog) Feb 12, 2015 - In another sign Sanofi is struggling to remake itself, the drug maker is shrinking its oncology business and folding it into the Genzyme unit as part of a wider R&D reorganization.
read article (paid subscription required) 

Study: Physicians Report Few Requests By Patients For ‘Unnecessary’ Treatments

(Kaiser Health News) Feb 12, 2015 - Though medically unnecessary tests and procedures are often blamed for the nation’s high health care costs, patients’ requests for such superfluous treatments may not be what triggers them, suggests a study published today in the JAMA Oncology.
read article 

New Affordable Care Act Initiative to Encourage Better Oncology Care

( Feb 12, 2015 - The U.S. Department of Health and Human Services (HHS) today announced a new multi-payer payment and care delivery model to support better care coordination for cancer care as part of the Department’s ongoing efforts to improve the quality of care patients receive and spend health care dollars more wisely, contributing to healthier communities.
read press release 

Sanofi to Shrink Cancer Operations, Narrow Focus of Genzyme R&D

(Bloomberg) Feb 11, 2015 - Sanofi, France’s largest drugmaker, plans to shrink its embattled cancer business and narrow the focus within Genzyme’s research unit as part of a wider reorganization of research and development.
read article 

Lenvatinib Shows Promise For Patients With Radioiodine-Refractory Thyroid Cancer

(MD Anderson) Feb 11, 2015 - In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.
read press release 

Amgen Announces FDA Advisory Committees to Review Talimogene Laherparepvec For the Treatment of Patients With Metastatic Melanoma

(Amgen) Feb 11, 2015 - Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.
read corporate press release 

Medicare, Medicaid Ready for ICD-10, Report Suggests

(Medscape Medical News) Feb 10, 2015 - Will the rollout of the controversial ICD-10 diagnostic codes on October 1 be as botched as the debut of under the Affordable Care Act, or will it proceed smoothly, by and large?
read article (free registration required) 

The Return of the Egg? New Dietary Guidelines May Downplay Cholesterol Risks

( Feb 11, 2015 - Recommendations from the Dietary Guidelines Advisory Committee, which are now under review, are expected to downplay the importance of lowering cholesterol intake.
read article 

Rite Aid to Buy Pharmacy Benefit Manager EnvisionRx for $2 Billion

(Wall Street Journal) Feb 11, 2015 - Rite Aid Corp. agreed to buy pharmacy-benefit manager Envision Pharmaceutical Services for about $2 billion from investment firm TPG, a deal that would better position the company to compete in a rapidly changing health-care marketplace.
read article (paid subscription required) 

Google Adds Fact-checked Medical Information to Search

( Feb 10, 2015 - Basic information on symptoms, treatments, and the rarity of the conditions will now pop up in the Knowledge Graph.
read article 

The Coming Boom In Brain Medicines

(Forbes Magazine) Mar 2, 2015 - Advances in genetics and clinical science could lead to a flood of new treatments for depression, Alzheimer's, and even schizophrenia. That's giving hope to millions of patients--and rebooting one of the biggest markets in the history of the drug business.
read article 

Bringing Incurable Optimism to the Fight Against Cancer

(Bloomberg) Feb 10, 2015 - For Tom Galjour these days, it’s all about the bloodwork.
read article 

CMS Issues Final Rule on Medicare Advantage, Part D Changes for 2016

(ACCC) Feb 6, 2015 - On Feb. 6, the Centers for Medicare & Medicaid Services (CMS) issued a rule that makes policy and technical changes to Medicare Advantage (MA) and the Medicare Part D prescription drug program for contract year 2016.
read article 

New Partnership Launches to Empower People Diagnosed with Lymphoma

(ACCC) Feb 10, 2015 - The Leukemia & Lymphoma Society (LLS) together with the Lymphoma Research Foundation (LRF), CancerCare, the Association of Community Cancer Centers (ACCC) and Genentech announced the launch of a new partnership, the Alliance for Resource Collaboration in Hematology (ARCH).
read press release 

iKnowMed Named Top-Performing Electronic Health Record (EHR) for Oncology and Hematology Practices for the Fourth Consecutive Year

(The US Oncology Network) Feb 11, 2015 - For the fourth consecutive year, iKnowMedSM has been named the top-ranked electronic health record (EHR) platform for oncologists and hematologists by Black Book Rankings, a division of Black Book Market Research, an unbiased source for polling, surveys and market research.
read corporate press release 

South Carolina Oncology Associates Choose Flatiron Health OncoEMR®

(Flatiron Health) Feb 11, 2015 — Flatiron Health today announced that South Carolina Oncology Associates, one of the only physician-owned, comprehensive cancer treatment center in South Carolina, has selected OncoEMR® to better manage clinical workflows and help transform their delivery of high quality cancer care.
read corporate press release 

CEO Says Tulsa Cancer Institute Denies Sale Talks

(Stillwater News Press [Stillwater, OK]) Feb 11, 2015 - Stillwater Medical Center and Tulsa Cancer Institute officials agree that Stillwater and the surrounding area need access to high quality cancer care close to home but they don’t seem to agree on much beyond that.
read article 

UTSW Receives Key NCI Funding to Plan First US Center for Heavy Ion Radiation Therapy Research

(UT Southwestern) Feb 10, 2015 – UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country’s first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.
read press release 

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer

(TheStreet) Feb 11, 2015 - Oncolytics Biotech® Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of ovarian cancer.
read article 

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer

(NASDAQ) Feb 11, 2015 - Advaxis, Inc. has entered into a clinical trial collaboration agreement with Incyte Corporation to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360).
read article 

Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent

(CNNMoney) Feb 11, 2015 - Immune Design, a clinical-stage immunotherapy company, today announced the start of a Phase 1 clinical trial of G100 in combination with radiation therapy in patients with metastatic sarcoma.
read article